EUCTR2014-004375-23-Outside-EU/EEA进行中（未招募）不适用
An open-label extension study to assess the safety andseizure frequency associated with long-term orallacosamide for uncontrolled primary generalizedtonic-clonic seizures in subjects with idiopathic generalizedepilepsy
CB BIOSCIENCES, Inc.0 个研究点目标入组 45 人开始时间: 2015年3月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subject completed the SP0961 (2014-004379-22) study
- •- Subject is expected to benefit from participation in an open-label extension study with Lacosamide, in the opinion of the investigator
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 5
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •- Subject meets the withdrawal criteria for SP0961 (2014-004379-22) or is experiencing an ongoing Serious Adverse Event (SAE)
研究者
相似试验
进行中（未招募）
不适用
An open label extension study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension. - NDhypertensionEUCTR2006-005473-21-ITOVARTIS FARMA68
进行中（未招募）
1 期
An open label extentsion study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 6 months -5 years old with hypertension.HypertensionEUCTR2006-005473-21-BEovartis Pharma Services AG66
进行中（未招募）
不适用
An open label extentsion study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension.HypertensionEUCTR2006-005473-21-HUovartis Pharma Services AG68
进行中（未招募）
不适用
An open label extentsion study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension.HypertensionEUCTR2006-005473-21-DEovartis Pharma Services AG68
进行中（未招募）
1 期
An open label extentsion study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension.MedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionHypertensionEUCTR2006-005473-21-FRovartis Pharma Services AG66